Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

16 Aug 2022
Go Back

RSV Human Challenge Case Study

Share this:

An international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified vaccinia virus Ankara RSV vaccine candidate. The company wanted to obtain proof of efficacy and additional safety data by Dec-21, (building on data from their initial “In-Human” study) before launching a global Phase III programme.

Other recent posts

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.

Contact hVIVO